COMPANY OVERVIEW

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

---

LOCATION

San Diego, CA, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://www.primmunerx.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Apr 8, 2022

Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 28, 2022

Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2022

Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)

Mar 10, 2022

Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Feb 24, 2022

Primmune Therapeutics to Participate in the 12th Annual Biocom Global Life Science Partnering Conference

For More Press Releases

---